Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Revenue of Ipsen S.A. (IPN.PA)
Revenue in 2023 (TTM): $3.49 B
According to Ipsen S.A.'s latest financial reports the company's current revenue (TTM) is $3.49 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Ipsen S.A.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $3.49 B | $2.89 B | $1.21 B | $797.62 M | $679.78 M |
| 2022 | $3.33 B | $2.77 B | $1.19 B | $743.08 M | $684.21 M |
| 2021 | $2.9 B | $2.44 B | $1.12 B | $832.85 M | $682.11 M |
| 2020 | $2.83 B | $2.32 B | $838.02 M | $560.26 M | $578.09 M |
| 2019 | $2.84 B | $2.33 B | $161.08 M | $-36,710,885 | $-57,914,586 |
| 2018 | $2.48 B | $2 B | $680.42 M | $522.39 M | $410.89 M |
| 2017 | $2.12 B | $1.72 B | $513.64 M | $392.43 M | $287.25 M |
| 2016 | $1.76 B | $1.39 B | $408.25 M | $316.37 M | $238.3 M |
| 2015 | $1.6 B | $1.25 B | $370.91 M | $253.28 M | $200.33 M |
| 2014 | $1.41 B | $1.08 B | $298.75 M | $219.74 M | $161.93 M |
| 2013 | $1.35 B | $1.03 B | $265.63 M | $212.56 M | $160.92 M |
| 2012 | $1.35 B | $1.08 B | $209.07 M | $126.86 M | $-31,110,365 |
| 2011 | $1.3 B | $1.04 B | $156.12 M | $43.64 M | $447.28 K |
| 2010 | $1.23 B | $985.4 M | $175.5 M | $132.28 M | $100.93 M |
| 2009 | $1.17 B | $922.6 M | $228.54 M | $176.49 M | $165.8 M |
| 2008 | $1.1 B | $863.11 M | $260.33 M | $191.11 M | $155.78 M |
| 2007 | $1.05 B | $838.37 M | $262.73 M | $218.22 M | $159.36 M |
| 2006 | $908.99 M | $717.65 M | $250.82 M | $195.87 M | $151.91 M |
| 2005 | $832.02 M | $645.47 M | $200.86 M | $163.52 M | $125.78 M |
| 2004 | $763.74 M | $577.75 M | $158.94 M | $121.99 M | $87.56 M |